KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Asset Writedowns and Impairment (2017 - 2025)

Historic Asset Writedowns and Impairment for Vertex Pharmaceuticals (VRTX) over the last 11 years, with Q1 2025 value amounting to $379.0 million.

  • Vertex Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $379.0 million in Q1 2025 from the same period last year, while for Dec 2025 it was $379.0 million, marking a year-over-year change of. This contributed to the annual value of $379.0 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Asset Writedowns and Impairment of $379.0 million as of Q1 2025.
  • Vertex Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $379.0 million during Q1 2025, with a 5-year trough of $379.0 million in Q1 2025.